The use of n-blockers as topical ophthalmic preparations to reduce the intraocular pressure marked the start of a new era in the medical management of glaucoma, because of their efficacy, prolonged therapeutic action, and few serious systemic and ocular adverse effects. 2 As a result they became the first choice for the medical treatment of glaucoma. However, in recent years the increasing number of systemic and ocular adverse effects have led to their more cautious use despite the development of newer drugs with supposedly fewer side effects. 3 In the United Kingdom there are five ,3-blockers available as ophthalmic topical preparations approved for clinical use, namely, betaxolol, carteolol, levobunolol, metipranolol (now withdrawn), and timolol. Metipranolol (1,-(4 acetoxy-2,3,5-trimethylphenyloxy)-3-isopropylacyno-propan-2-ol) was introduced in the UK in 1986 with the proprietary name of Glauline and available in three strengths: 0o 1%, 0 3%, and 0-6%. It is a non-selective f-blocker with no intrinsic sympathomimetic or membrane stabilising properties and only slight local anaesthetic activity. 4 The efficacy of metipranolol in lowering intraocular pressure has been reported in several studies,5 and so have the adverse effects, which are similar to those of other ophthalmic topical (-blockers. The ocular adverse effects attributed to metipranolol have included: subjectively, burning or stinging on instillation, eye pain or uncomfortable dryness, foreign body sensation, itching, blurred vision; objectively, allergic blepharoconjunctivitis, conjunctival hyperaemia, punctate keratopathy, corneal anaesthesia, and dry eye syndrome.'0 It has been suggested that metipranolol is less tolerated than the other n-blockers because of the stinging and burning sensation on instillation.7 ' This paper documents for the first time case histories of some patients receiving this drug for the treatment of glaucoma who developed granulomatous anterior uveitis. The clinical details are reviewed briefly, and photographic evidence submitted. The clinical presentation and behaviour of the affected eyes are analysed.
Methods and materials
At the beginning of 1990 a cluster of cases of severe metipranolol-associated blepharoconjunctivitis focused attention on this drug. The reaction was more severe than usually seen and two patients (three eyes) had coincidental granulomatous anterior uveitis. The bottles of metipranolol were collected from all the patients who suffered from both forms of adverse reactions and their batch numbers identified. There was no consistency in the batch numbers to suggest faulty preparation or contamination of the drug. During this inquiry six more patients were identified in the clinics and ophthalmic ward with granulomatous anterior uveitis while being treated with metipranolol for glaucoma. There were now eight patients, 15 eyes, with granulomatous anterior uveitis, all receiving metipranolol and no othercommon denominator.
In view of these findings we decided to review the case notes of all the patients in the department using metipranolol in any of its three strengths. The patients were identified through the Drug Register in the Pharmacy Department, the records from January 1989 to March 1990 being examined. All the patients on metipranolol 0-6% were then invited for an ocular examination.
Results
Two hundred and forty-seven case notes of patients treated with metipranolol in all strengths were reviewed. There were 109 case notes of patients using metipranolol 0-6% and 76 patients from this group attended special metipranolol clinics for examination. Eleven patients had active granulomatous anterior uveitis when seen in either special or normal clinics, and four had had attacks, well documented in the case notes, but had quiet eyes when examined. In total there were 15 patients (13-8% of the patients on metipranolol 0-6%) with presumed metipranolol-associated granulomatous anterior uveitis, 11 of these with bilateral attacks and four with unilateral, making a total of 26 eyes. All There were no systemic or ocular disorders common to these patients. Two of them had diabetes mellitus (one insulin-dependent and the other on oral hypoglycaemics).
Six eyes of five patients had intraocular surgery prior to treatment with metipranolol of any strength and the development of granulomatous anterior uveitis. A total of nine intraocular operations had been performed on the six eyes: cataract surgery (five eyes), trabeculectomy (two eyes), retinal detachment surgery with silicone oil (one eye). One eye (case 14, LE) had retinal detachment surgery, cataract extraction, and trabeculectomy at different times and developed the first episode of granulomatous anterior uveitis at least 15 months after the last operation.
Analysis of the drug history of the 15 patients with metipranolol-associated granulomatous anterior uveitis was unproductive. There was no common factor between the various systemic medications. Thirteen eyes ofeight patients were on additional topical ophthalmic medications when they developed granulomatous anterior Table 2 .
Of the 26 eyes identified with uveitis 16 had further episodes while they remained on the metipranolol drops. The mean interval between the first and second episodes in these 16 eyes was 4 75 months (range 3-9 months). Nine of the 16 eyes had a third episode after a mean interval of 3-6 months (range 1-10 months). Four out of 26 eyes had four episodes each; the intervals between the third and fourth episodes ranged from one to 6 months, mean 2-5 months. Only one of these eyes developed a fifth episode of uveitis after a period of six months (Tables 3 and  4) .
The 56 episodes of granulomatous anterior uveitis were managed in various ways, as summarised in Table 5 .
Briefreports on some ofthe 15 bilateral anterior uveitis with mutton-fat keratic precipitates, posterior synechiae (Fig 2) , and uncontrolled IOPs. The (Table 5 ). The IOP of eyes with metipranolol associated side effects is the subject of a separate investigation.
All but six episodes of anterior uveitis were treated with topical steroids (Table 5 ). The average resolution period of the anterior uveitis when treated ranged from 2-6 to 4-4 weeks, but in the six eyes which received no topical steroids and were treated only by discontinuation of the metipranolol drops the average time for recovery was longer at six weeks. This difference was statistically significant (p<0-0125). A 
